Dr. Mark Ware

13
Introduction to the Endocannabinoid System Dr Mark A. Ware MD MRCP MSc Alan Edwards Pain Management Unit McGill University Montreal, Quebec, Canada

description

 

Transcript of Dr. Mark Ware

Page 1: Dr. Mark Ware

Introduction to the Endocannabinoid System

Dr Mark A. Ware MD MRCP MScAlan Edwards Pain Management Unit

McGill UniversityMontreal, Quebec, Canada

Page 2: Dr. Mark Ware

Learning objectives

• Review components and role of endocannabinoid system (ECS)

• Summarize pharmacological strategies to harness ECS

Page 3: Dr. Mark Ware

1. Mack A & Joy J., 2001.2. Notcutt W., 2004.

Cannabinoids and Opioids: A Historical Perspective

500 BC 1522 1804

1900’s

19701817

1988

1900’s

1964 1998

1975

Earliest known reference for opium-based elixir

3000 BC

First evidence of medicinal use in China

1800’s

W.B. O’Shaughnessey’swork popularizes cannabis use

Medicinal cannabis use declines

Paracelsus reference to “laudanum”, opium-based elixir, as a potent painkiller

1804: Morphine extracted from opium poppy plant

1817: Morphine first marketed in Germany as analgesic

Morphine analogs synthesized: 1874: Diacetylmorphine (heroin)1900s: codeine, dihydromorphine, oxycodone, pethidine, oxymorphone

1970s: Discovery of opioid receptors – µ (mu), к (kappa), δ (delta)

1975: Discovery of endogenous opioid peptides - endorphins

9-THC identified as main psychoactive agent in Cannabis sativa plant

1988: CB1 receptor identified.1990: CB1 receptor cloned1992: Anandamide discovered, CB2 receptor identified1993: CB2 receptor cloned1998: Endogenous cannabinoid ligands shown to be analgesic

1874

Cannabinoids

Opioids

Page 4: Dr. Mark Ware
Page 5: Dr. Mark Ware

Source: Health Canada January 2013

Page 6: Dr. Mark Ware

Cannabinoid mechanisms

Page 7: Dr. Mark Ware

Peripheral CB1 receptors

Page 8: Dr. Mark Ware

1. Cappendijk S., 2010.2. Hanks G et al., 2003.

3. Mackie K., 2006.

Mechanisms Of ActionCannabinoidsOpioids

Page 9: Dr. Mark Ware

Endocannabinoid regulation

Page 10: Dr. Mark Ware

Metabolic pathways of endocannabinoids

Page 11: Dr. Mark Ware

Cannabinoids as immune modulators

Nature Rev Drug Disc 2008;7:438-455

Page 12: Dr. Mark Ware

Harnessing the cannabinoid system

• Exogenous compounds– Phytocannabinoids

• THC, CBD, combinations– Synthetic cannabinoids

• Nabilone

• Endogenous manipulation• FAAH inhibitors• MAGL, DAGL inhibitors

• Receptor targets– CB1, CB2, TRPV1, PPAR, 5-HT, other…

Page 13: Dr. Mark Ware

Some new approaches• Novel THC formulations

– Oral THC preparations– Microspheres– Topical delivery– Buccal mucoadhesive preparations– Portable vapourizers/aerosols– Rectal administration

• Therapies that increase endocannabinoid levels– Running– Osteopathic manipulation